Outcomes of the current approved triplet combinations for relapsed/refractory MM in genomic high-risk patients
| Trial . | Regimen . | Study design (primary endpoint) . | Study definition of HR . | No. HR patients (%) . | PFS rates . | MRD− (%) . |
|---|---|---|---|---|---|---|
| CANDOR110 | D-Kd vs Kd | Randomized, open-label, controlled, phase 3, RRMM (PFS) | t(4;14), t(14;16), or del(17p) | 74 (16) | Median PFS: NE (D-Kd) vs 15.8 mo (Kd) | — |
| ELOQUENT-3117 | Elo-Pd vs Pd | Randomized, open-label, controlled, phase 3, RRMM (PFS) | ISS stage II or III and del(17p), t(4;14), t(14;16) | 27 (23) | Median PFS: 6.2 mo (HR) vs 10.3 mo (SR) (Elo-Pd) 2.2 mo (HR) vs 5.2 mo (SR) (Pd) | — |
| CASTOR100,105 | D-Vd vs Vd | Randomized, open-label, controlled phase 3, RRMM (PFS) | del(17p), t(4;14), t(14;16) | 91 (18) | Median PFS: 12.6 mo (HR) vs 16.6 mo (SR) (D-Vd) 6.2 mo (HR) vs 6.6 mo (SR) (Vd) | 15% (HR) vs 13% (SR) (D-Vd) 0 (HR) vs 3% (SR) (Vd) |
| OPTIMISMM109 | PVd vs Vd | Randomized, open-label, controlled, phase 3, RRMM (PFS) | del(17p), t(4;14), t(14;16) | 110 (20) | Median PFS: 8.44 mo (HR) vs 11.2 mo (ITT) (PVd) 5.32 mo (HR) vs 7.1 (ITT) (Vd) | — |
| POLLUX101,105 | D-Rd vs Rd | Randomized, open-label, controlled, phase 3, RRMM (PFS) | del(17p), t(4;14), t(14;16) | 65 (11) | Median PFS: 26.8 mo (HR) vs 52.0 mo (SR) (D-Rd) 8.3 mo (HR) vs 18.6 mo (SR) (Rd) | 29% (HR) vs 35% (SR) (D-Rd) 3% (HR) vs 9% (SR) (Rd) |
| ASPIRE102 | KRd vs Rd | Randomized, open-label, controlled, phase 3, RRMM (PFS) | del(17p), t(4;14), t(14;16) | 100 (13) | Median PFS: 23.1 mos (HR) vs 29.6 mo (SR) (KRd) 13.9 mo (HR) vs 19.5 mo (SR) (Rd) | — |
| ENDEAVOR118 | Kd vs Vd | Randomized, open-label, controlled, phase 3, RRMM (PFS) | del(17p), t(4;14), t(14;16) | 210 (23) | Median PFS: 8.8 mo (HR) vs NE (SR) (Kd) 6.0 mo (HR) vs 10.2 mo (SR) (Vd) | — |
| Trial . | Regimen . | Study design (primary endpoint) . | Study definition of HR . | No. HR patients (%) . | PFS rates . | MRD− (%) . |
|---|---|---|---|---|---|---|
| CANDOR110 | D-Kd vs Kd | Randomized, open-label, controlled, phase 3, RRMM (PFS) | t(4;14), t(14;16), or del(17p) | 74 (16) | Median PFS: NE (D-Kd) vs 15.8 mo (Kd) | — |
| ELOQUENT-3117 | Elo-Pd vs Pd | Randomized, open-label, controlled, phase 3, RRMM (PFS) | ISS stage II or III and del(17p), t(4;14), t(14;16) | 27 (23) | Median PFS: 6.2 mo (HR) vs 10.3 mo (SR) (Elo-Pd) 2.2 mo (HR) vs 5.2 mo (SR) (Pd) | — |
| CASTOR100,105 | D-Vd vs Vd | Randomized, open-label, controlled phase 3, RRMM (PFS) | del(17p), t(4;14), t(14;16) | 91 (18) | Median PFS: 12.6 mo (HR) vs 16.6 mo (SR) (D-Vd) 6.2 mo (HR) vs 6.6 mo (SR) (Vd) | 15% (HR) vs 13% (SR) (D-Vd) 0 (HR) vs 3% (SR) (Vd) |
| OPTIMISMM109 | PVd vs Vd | Randomized, open-label, controlled, phase 3, RRMM (PFS) | del(17p), t(4;14), t(14;16) | 110 (20) | Median PFS: 8.44 mo (HR) vs 11.2 mo (ITT) (PVd) 5.32 mo (HR) vs 7.1 (ITT) (Vd) | — |
| POLLUX101,105 | D-Rd vs Rd | Randomized, open-label, controlled, phase 3, RRMM (PFS) | del(17p), t(4;14), t(14;16) | 65 (11) | Median PFS: 26.8 mo (HR) vs 52.0 mo (SR) (D-Rd) 8.3 mo (HR) vs 18.6 mo (SR) (Rd) | 29% (HR) vs 35% (SR) (D-Rd) 3% (HR) vs 9% (SR) (Rd) |
| ASPIRE102 | KRd vs Rd | Randomized, open-label, controlled, phase 3, RRMM (PFS) | del(17p), t(4;14), t(14;16) | 100 (13) | Median PFS: 23.1 mos (HR) vs 29.6 mo (SR) (KRd) 13.9 mo (HR) vs 19.5 mo (SR) (Rd) | — |
| ENDEAVOR118 | Kd vs Vd | Randomized, open-label, controlled, phase 3, RRMM (PFS) | del(17p), t(4;14), t(14;16) | 210 (23) | Median PFS: 8.8 mo (HR) vs NE (SR) (Kd) 6.0 mo (HR) vs 10.2 mo (SR) (Vd) | — |
D, daratumumab; Elo, elotuzumab; HR, high-risk; ITT, intention-to-treat; Kd, carfilzomib, dexamethasone; KRd, carfilzomib, lenalidomide, dexamethasone; NE, not estimable; NR, not reached; Pd, pomalidomide, dexamethasone; PVd, pomalidomide, bortezomib, dexamethasone; Rd, lenalidomide, dexamethasone; SR, standard risk; Vd, bortezomib, dexamethasone.